The cell is saying, I can't maintain myself, so I'll become something else
In the intricate theater of the human immune system, Brazilian researchers have uncovered a molecular guardian — the protein XPC — whose role in repairing DNA during immune cell replication may hold the key to understanding why the body sometimes turns against itself. Published in Nature Communications, the work by scientists from UFRJ and international collaborators reveals that when this sentinel falters in Th17 immune cells, the resulting disorder may give rise to autoimmune conditions like psoriasis and multiple sclerosis. The discovery invites a more precise and respectful approach to treating these diseases — one that seeks balance rather than suppression.
- Every time the immune system mobilizes against infection, its cells must copy their DNA at speed — a process riddled with risk, where accumulated errors can transform defenders into threats.
- Researchers found that XPC, a protein previously linked only to a rare skin disorder, is in fact a critical DNA repair sentinel inside Th17 immune cells, and its absence sends those cells into metabolic and functional disarray.
- When XPC fails, Th17 cells don't simply break down — they shapeshift, adopting traits of an entirely different class of immune cell, revealing an unsettling plasticity at the heart of immune identity.
- Current autoimmune therapies bluntly block inflammatory signals, but this research points toward a more surgical intervention: tuning XPC activity to quiet runaway inflammation without disarming the body's defenses against real pathogens.
- Preclinical trials in multiple sclerosis models are already underway, as scientists race to find the precise threshold where immune protection ends and autoimmune destruction begins.
A research team led by Jefferson Antônio Leite of Brazil's Federal University of Rio de Janeiro, working alongside collaborators in São Paulo, the United States, and Germany, has identified a protein called XPC as a critical guardian of DNA integrity in Th17 immune cells. The findings, published in Nature Communications, shed new light on how autoimmune diseases like psoriasis and multiple sclerosis may originate at the molecular level.
When the body faces infection, immune cells called lymphocytes must divide rapidly — a process that inherently risks copying errors. XPC acts as a sentinel within this process, detecting DNA damage and coordinating repairs in Th17 cells, whose numbers surge significantly during immune responses. Leite's team observed that XPC expression rises sharply as Th17 cells form, suggesting these cells are especially dependent on this repair mechanism to remain functional.
Though XPC was previously known mainly through xeroderma pigmentosum — a rare disorder causing extreme sun sensitivity and elevated skin cancer risk — the new research reveals its equally vital role in everyday immune function. Without XPC, cells accumulate oxidative DNA damage, metabolic processes falter, and production of IL-17, a key inflammatory signaling molecule, drops significantly. More strikingly, XPC-deficient Th17 cells sometimes transform, taking on characteristics of regulatory T cells — a discovery that hints at a deep link between DNA repair capacity and immune cell identity itself.
The therapeutic implications are considerable. Rather than broadly suppressing inflammation as current treatments do, researchers envision modulating XPC activity to selectively quiet autoimmune responses while preserving the immune system's ability to fight genuine threats. Leite's team is already testing this approach in preclinical multiple sclerosis models, seeking the precise threshold at which XPC levels tip the balance between protection and pathology — a pursuit that demands respect for the immune system's profound complexity.
A team of researchers from Brazil's Federal University of Rio de Janeiro and collaborators in São Paulo, the United States, and Germany have identified a crucial mechanism that controls how immune cells repair their own DNA while multiplying to fight infection. The discovery, published in April in Nature Communications, centers on a protein called XPC and its role in maintaining the health of specialized immune cells known as Th17 cells. The finding opens a new window onto understanding autoimmune diseases like psoriasis and multiple sclerosis—conditions that arise when this same protective mechanism goes wrong.
When the body encounters a bacterial, viral, or fungal threat, it launches a rapid mobilization of immune cells called lymphocytes. These cells must divide quickly to mount an effective defense, but rapid copying of DNA is inherently risky. Just as a photocopier produces degraded images when settings drift too far, immune cells that accumulate errors during replication can malfunction, leaving the body vulnerable. This is where XPC enters the picture. The protein acts as a sentinel, detecting damage in the DNA strand and coordinating repairs to keep cells functioning properly. Jefferson Antônio Leite, the lead author and a professor at UFRJ's Institute of Microbiology, observed that XPC expression increases significantly during the formation of Th17 cells, suggesting these cells depend on this repair mechanism to maintain their integrity.
The XPC protein was already known to science through a rare genetic disorder called xeroderma pigmentosum, which leaves patients acutely vulnerable to sunlight and carries a dramatically elevated risk of skin cancer. What the new research reveals is that this same protein plays an equally vital role in the immune system's day-to-day operations. When XPC is absent or dysfunctional, cells accumulate DNA damage—particularly oxidative damage that generates harmful free radicals. The consequences ripple through the cell's internal machinery: metabolic processes falter, and production of IL-17, one of the key signaling molecules that Th17 cells produce, drops sharply.
XPC does not work alone. The protein functions as part of a coordinated network of DNA repair mechanisms, each supporting the others in a delicate balance. When this coordination breaks down, the entire system destabilizes. Leite and his team made an unexpected discovery: when XPC is absent, Th17 cells sometimes shift their behavior, acquiring characteristics similar to regulatory T cells—a different immune cell type whose discovery earned a Nobel Prize in Medicine. This plasticity hints at a deeper connection between DNA repair capacity and immune cell identity.
The implications for treatment are substantial. Autoimmune diseases arise when immune cells attack the body's own tissues, often because the normal brakes on inflammation have failed. If researchers can understand and modulate XPC activity, they might be able to dial down the inflammatory response in conditions like psoriasis, inflammatory bowel disease, type 1 diabetes, and rheumatoid arthritis. Leite's team has already begun testing this approach in preclinical models of multiple sclerosis. But the challenge is delicate: suppress XPC too much and you risk leaving the body defenseless against genuine threats. The researchers are now investigating the threshold at which XPC production tips the balance between autoimmunity and protective immunity. Current treatments for autoimmune disease rely on blocking IL-17 directly, but Leite suggests a different path may be possible—one that preserves the body's ability to produce enough of these signaling molecules to fight bacteria and viruses while preventing the runaway inflammation that characterizes autoimmune disease. The work points toward a more nuanced approach to immune modulation, one that respects the system's complexity rather than simply shutting it down.
Citações Notáveis
During Th17 cell formation, XPC expression increases, indicating these cells depend on this mechanism to maintain their integrity— Jefferson Antônio Leite, UFRJ Institute of Microbiology
The study opens perspectives for treating autoimmune diseases while evaluating the threshold between XPC production in autoimmune versus pathogen-caused diseases— Jefferson Antônio Leite
A Conversa do Hearth Outra perspectiva sobre a história
So this protein XPC—it's been known for decades through this rare genetic disease. What made researchers think to look at it in immune cells?
The connection wasn't obvious at first. They were studying how Th17 cells—these workhorse immune cells—manage to multiply rapidly without falling apart. And when they looked at what proteins were being activated during that process, XPC kept showing up. It was like finding a familiar tool in an unexpected place.
And when XPC isn't working, the cells start accumulating damage. But you mentioned something interesting—they don't just die or malfunction. They sometimes change into a different type of cell entirely.
Right. That's the puzzle. When XPC is missing, some Th17 cells acquire characteristics of regulatory T cells—cells that actually suppress inflammation. It's as if the cell is saying, "I can't maintain myself properly, so I'll become something else."
That sounds like it could be useful for autoimmune disease. But Leite seemed cautious about just blocking XPC everywhere.
Because you'd lose protection. These cells are essential for fighting real infections. If you shut down XPC in all immune cells, you might prevent psoriasis but leave someone defenseless against bacteria. The real therapeutic target is probably much more specific—maybe just in certain cell types, or at certain times.
So the next phase is figuring out where to intervene without breaking the immune system's ability to protect.
Exactly. They're testing in multiple sclerosis models now, but the bigger question is: can you find a threshold where you reduce autoimmune disease without sacrificing immunity to pathogens? That's the work ahead.